Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S1556086416302532-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (69kB) |
|
|
Text
accepted_manuscript.pdf - Accepted Version Available under License Publisher holds Copyright. Download (6MB) | Preview |
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Rauch, Daniel, Ochsenbein, Adrian |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1556-1380 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Marianne Zahn |
Date Deposited: |
27 Dec 2016 15:29 |
Last Modified: |
05 Dec 2022 15:00 |
Publisher DOI: |
10.1016/S1556-0864(16)30253-2 |
PubMed ID: |
27198283 |
BORIS DOI: |
10.7892/boris.92046 |
URI: |
https://boris.unibe.ch/id/eprint/92046 |
Actions (login required)
 |
Edit item |